Although recurrent chromosomal alterations occur in chronic lymphocytic leukemia (CLL), relatively few affected tumor suppressors and oncogenes have been implicated. To improve genetic characterization of CLL, we performed high-resolution gene copy number analysis of 20 CLL patients using oligonucleotide array comparative genomic hybridization (aCGH). The most recurrent losses were observed in 13q and 11q with variable sizes. The 11q losses varied between 7.44 Mb and 41.72 Mb in size and targeted ATM among others. Lost regions in 13q were generally smaller, spanning from 0.79 Mb to 29.33 Mb. The minimal common region (158 kb) in 13q14.3, which was also homozygously deleted in some cases, harbored five genes: TRIM13, KCNRG, DLEU2, DLEU1, and FAM10A4. Additionally, two micro-RNA genes (MIRN15A and MIRN16-1) locate to the region. New cryptic losses were detected in 1q23.2→q23.3, 3p21.31, 16pter→p13.3, 17p13.3→p13.2, 17q25.3→qter, and 22q11.22. In conclusion, our oligonucleotide aCGH study revealed novel aberrations and provided detailed genomic profiles of the altered regions.

1.
Auer RL, Jones C, Mullenbach RA, Syndercombe-Court D, Milligan DW, et al: Role for CCG-trinucleotide repeats in the pathogenesis of chronic lymphocytic leukemia. Blood 97:509–515 (2001).
2.
Bea S, Lopez-Guillermo A, Ribas M, Puig X, Pinyol M, et al: Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter’s syndrome). Am J Pathol 161:957–968 (2002).
3.
Bullrich F, Veronese ML, Kitada S, Jurlander J, Caligiuri MA, et al: Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood 88:3109–3115 (1996).
4.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524–15529 (2002).
5.
Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, et al: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609–4614 (2002).
6.
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944–13949 (2005).
7.
Corcoran MM, Rasool O, Liu Y, Iyengar A, Grander D, et al: Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood 91:1382–1390 (1998).
8.
Corcoran MM, Hammarsund M, Zhu C, Lerner M, Kapanadze B, et al: DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse. Genes Chromosomes Cancer 40:285–297 (2004).
9.
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840–1847 (1999).
10.
de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, et al: Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 13:1827–1837 (2004).
11.
Döhner H, Stilgenbauer S, James MR, Benner A, Weilguni T, et al: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89:2516–2522 (1997).
12.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916 (2000).
13.
Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, et al: Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 6:246–250 (1992).
14.
Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, et al: p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413–5417 (1991).
15.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848–1854 (1999).
16.
Ji L, Minna JD, Roth JA: 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol 1:79–92 (2005).
17.
Karhu R, Tobin G, Thunberg U, Vilpo L, Sundström C, et al: More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia. Genes Chromosomes Cancer 37:417–420 (2003).
18.
Knuutila S, Elonen E, Teerenhovi L, Rossi L, Leskinen R, et al: Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. N Engl J Med 314:865–869 (1986).
19.
Knuutila S, Autio K, Aalto Y: Online access to CGH data of DNA sequence copy number changes. Am J Pathol 157:689 (2000).
20.
Kohlhammer H, Schwaenen C, Wessendorf S, Holzmann K, Kestler HA, et al: Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 104:795–801 (2004).
21.
Koski T, Karhu R, Visakorpi T, Vilpo L, Knuutila S, Vilpo J: Complex chromosomal aberrations in chronic lymphocytic leukemia are associated with cellular drug and irradiation resistance. Eur J Haematol 65:32–39 (2000).
22.
Kröber A, Seiler T, Benner A, Bullinger L, Bruckle E, et al: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410–1416 (2002).
23.
Kuppers R: Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251–262 (2005).
24.
La Starza R, Barba G, Matteucci C, Crescenzi B, Romoli S, et al: Chronic lymphocytic leukaemia. Is terminal del(14)(q24) a new marker for prognostic stratification? Leuk Res 30:1569–1572 (2006).
25.
Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, et al: Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 15:2463–2473 (1997).
26.
Monni O, Knuutila S: 11q deletions in hematological malignancies. Leuk Lymphoma 40:259–266 (2001).
27.
Oscier DG, Thompsett A, Zhu D, Stevenson FK: Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 89:4153–4160 (1997).
28.
Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, et al: Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177–1184 (2002).
29.
Ottaggio L, Viaggi S, Zunino A, Zupo S, Rossi E, et al: Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression. Haematologica 88:769–777 (2003).
30.
Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, et al: Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 109:1202–1210 (2007).
31.
Pinkel D, Segraves R, Sudar D, Clark S, Poole I, et al: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207–211 (1998).
32.
Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, et al: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41–46 (1999).
33.
Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, et al: Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105:4445–4454 (2005).
34.
Sankar M, Tanaka K, Kumaravel TS, Arif M, Shintani T, et al: Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia 12:510–516 (1998).
35.
Schaffner C, Stilgenbauer S, Rappold GA, Döhner H, Lichter P: Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94:748–753 (1999).
36.
Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, et al: Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 101:1039–1044 (2004).
37.
Seiler T, Döhner H, Stilgenbauer S: Risk stratification in chronic lymphocytic leukemia. Semin Oncol 33:186–194 (2006).
38.
Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, et al: Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 353:26–29 (1999).
39.
Stilgenbauer S, Liebisch P, James MR, Schröder M, Schlegelberger B, et al: Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3–q23.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 93:11837–11841 (1996).
40.
Tyybäkinoja A, Saarinen-Pihkala U, Elonen E, Knuutila S: Amplified, lost, and fused genes in 11q23–25 amplicon in acute myeloid leukemia, an array-CGH study. Genes Chromosomes Cancer 45:257–264 (2006).
41.
Zhu Y, Monni O, El-Rifai W, Siitonen SM, Vilpo L, et al: Discontinuous deletions at 11q23 in B cell chronic lymphocytic leukemia. Leukemia 13:708–712 (1999).
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.